Simvastatin (statins) and Rhabdomyolysis: is the FAERS signal real?
Simvastatin (statins) ↔ Rhabdomyolysis
Statin-associated muscle injury runs a spectrum from common myalgia to rare, life-threatening rhabdomyolysis, and the risk is strongly dose-dependent: the 80 mg simvastatin dose carries a far higher myopathy rate than 20 mg, which is why the FDA restricted 80 mg use in 2011 and added it to the statin-drug-interaction warnings. The mechanism is well characterized — inhibiting HMG-CoA reductase depletes mevalonate-pathway intermediates in skeletal muscle — and serum simvastatin levels rise sharply when strong CYP3A4 inhibitors (clarithromycin, itraconazole, protease inhibitors, grapefruit) block its metabolism. This is a class effect, but simvastatin is among the most affected, which is why its labeled precautions are the strictest of the class. The disproportionality here reflects both a genuine effect and the very large numbers of patients on statins with routine creatine-kinase testing in symptomatic cases.
Regulatory basis: FDA simvastatin labeling changes and 80 mg dose restrictions (2011), including CYP3A4-interaction warnings. SEARCH randomized trial (80 mg vs 20 mg simvastatin myopathy comparison), Lancet 2010.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Muscle injury appears during exposure, typically within weeks of starting or escalating the dose |
| Strength | met | PRR 12 on a very large co-report count, with a steep dose–response |
| Consistency | met | Reproduced across statins, in the SEARCH randomized comparison, and in spontaneous-reporting databases |
| Specificity | partial | A class effect, not unique to simvastatin |
| Biological gradient | met | Risk rises clearly with dose (20 vs 80 mg) and with interacting drugs |
| Plausibility | met | HMG-CoA reductase inhibition depletes muscle mevalonate-pathway intermediates |
| Coherence | met | Fits the whole statin-myopathy literature and CK-monitoring practice |
| Experiment | met | Randomized dose comparison (SEARCH) showed markedly more myopathy at 80 mg |
| Analogy | met | Direct analogy to myopathy with other statins and with fibrate co-therapy |
This page's own qualitative read, not an automated/citation-gated assessment.